Editas Medicine announced the appointment of John D. Mendlein, Ph.D., CEO of aTyr Pharma, to its board of directors. Dr. Mendlein has served as CEO of aTyr Pharma since 2011, as well as executive chairman for the company from July 2010 to January 2016. He is also vice chairman of the board for Fate Therapeutics, a biopharmaceutical company, and holds board positions with Moderna Therapeutics, Pronutria Biosciences and the emerging companies board of BIO (Biotechnology Industry Organization).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.66 USD | +2.64% |
|
-1.69% | -54.00% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-54.00% | 383M | |
+16.59% | 44.44B | |
+42.89% | 40.03B | |
-10.62% | 37.68B | |
+29.92% | 31.46B | |
-9.23% | 27.29B | |
+12.34% | 26.29B | |
+41.53% | 13.8B | |
+31.49% | 12.46B | |
-7.40% | 11.26B |
- Stock Market
- Equities
- EDIT Stock
- News Editas Medicine, Inc.
- Editas Medicine Appoints John D. Mendlein to its Board of Directors